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Comparative In Vitro Studies on the Immunosuppressive Activities of 
Mycophenolic Acid, Bredinin, FK 506, Cyclosporine, and Rapamycin 
A. Zeevi, M. Woan, G.-Z. Yao, R. Venkataramanan, S. Todo, T.E. Starzl, and R.J. Duquesnoy 
OVER the past 25 years various immunosuppressive drugs have been screened for clinical usage in con-
trolling allograft rejection, autoimmune disease, and ma-
lignancy. In vitro methodologies have permitted a rapid 
assessment of potential new drugs. In this study we have 
compared the immunosuppressive effects of two purine 
synthesis inhibitors mycophenolic acid (MPA)I and bred-
inin (BR)2 to the known immunosuppressive drugs FK 
506, rapamycin (RAPA), and cyclosporine (CyA). A vari-
ety of culture systems were used to study the potency of 
different drugs and their mechanisms of action. Such 
models included T-cell activation via calcium-dependent 
(A23187 and phytohemagglutinin [PH A]) and calcium-
independent (interleukin-2 [IL-2J and phorbol myristic 
acetate [PMAJ) pathways. We tested the effect of immu-
nosuppressive drugs on freshly prepared peripheral blood 
lymphocytes (PBL), and transformed T- and non-T-cell 
lines. In addition, we also studied the combined effects of 
MPA, BR, and low doses of FK 506 and CyA in our 
system to determine whether there is any synergistic or 
additive effect between these drugs. 
MATERIALS AND METHODS 
Cells 
PBL were isolated by Ficoll-Hypaque density gradient centrifu-
gation of heparinized blood from healthy donors. Cells were 
resuspended in RPMI 1640 tissue culture medium (TCM) supple-
mented with 25 mmoVL Hepes buffer and 100 UlmL gentamycin 
and 5% normal human AB serum. 
Reagents 
FK 506 (Fujisawa Pharmaceuticals. Osaka. Japan) and CyA 
(Sandoz. Basel, Switzerland) were dissolved in methanol (1 mgt 
mL). MPA (Sigma Chemical Co, St Louis, Mo), BR (Sumitomo 
Chemical Co Ltd, Takarazuka, Japan), and RAPA (Wyeth-Ayerst 
Research. Rahway, NJ) were dissolved in ethanol. water, and 
methanol. respectively, before use. Calcium ionophore (A23187), 
PHA, and PMA were purchased from Sigma. 
Proliferative Responses of Lymphocytes 
Mitogen-Induced Proliferation Assays. Mononuclear cells 
were cultured in TCM at lOS cells/well (Nunc round bottom tissue 
culture plates) in the presence of A23187 (l ~miFI PHA (1%), or 
PMA (0.1 ~miF in a volume of 200 "L for 3 days. 
Mixed Lymphocyte Reaction (MLR assay). One-way MLR 
cultures were established with equal numbers (5 x 104/well) of 
responder and irradiated stimulator cells in TCM and incubated 
for 6 days. 
PLT Test. Alloreactive T cells (2 x 104/well) were incubated 
with lIP irradiated (2,000 rad) stimulator cells for 3 days. 
IL-2 Induced Proliferation. Alloreactive T-cell lines (2 x 104/ 
well) were incubated with 30 UlmL of recombinant IL-2 for 3 
days. [n all assays, proliferation was measured by the degree of 
3H-thymidine incorporation during the last 20 hours of incubation. 
Proliferative Responses of Various Cell Lines 
T-Iymphoma cell lines (DND41, Molt 13, Peer), EB virus-trans-
formed B-Iymphoblastoid cell lines (DT, CK, RK. DN), B-lym. 
phoma cell line (RPMI-1788), erythroleukemia cell line (K562), 
and promyelocytic cell line CHL-60) were maintained in TCM 
supplemented with 10% fetal calf serum (FCS). DND4I. Molt 13, 
and Peer were kindly provided by Dr C. Milcareck (Molecular 
Biology, University of Pittsburgh). RPMI-1788 and HL-60 were 
obtained from American Type Culture Collection (Rockville. 
Md). K562 was supplied by Dr T. Whiteside (Pittsburgh Canc"f 
Institute). Proliferation was measured after 72 hours of incubaul 1 
by 3H-thymidine incorporation. 
Drug Inhibition Assays 
The inhibitory effects of various drugs alone or in combination 
were measured at different concentrations. The % inhibition was 
calculated as follows: % inhibition = (I-cpm with drug/cpm 
without drug) x 100. 
The drug dose required to obtain 50% inhibition (lC50) was 
calculated by computer analysis, [BMP, using a nonlinear sigmoi· 
dal model curve fitting program (SAS. Inc, Cary, NC). 
RESULTS 
Effects of Immunosuppressive Drugs on T-Cell Proliferation 
Table I summarizes the IC50 values of five immunosup-
pressive drugs in the proliferation of T cells activated b:, 
Ca-dependent (A213187 and PHA) and Ca-independem 
(IL-2 and PMA) pathways. Both FK 506 and RAPA 
exerted profoundly inhibitory effects (IC50 less than I 
nmollL) of Ca-dependent T-cell proliferative responses 
whereas CyA and MPA required loo-fold higher concen-
trations. The IC50 of BR was about \04-fold higher than 
those for FK 506 and RAPA. 
In contrast to FK 506 and Cy A, RAPA caused profound 
inhibition of Ca-independent T-cell proliferation (Table 1). 
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IN VITRO STUDIES OF IMMUNOSUPPRESSANTS 
Table 1. Inhibitory Effects of Immunosuppressive Drugs on 
T-Cell Proliferation 
IC50 (nmollL) 
T-Cell Activation 
Pathways Mitogen FK 506 eyA RAPA MPA SR 
A23187 0.18 23 0.42 81 NT Ca-dependent PHA 0.72 857 0.87 232 8,919 
IL·2 No inhibition 0.61 119 7,637 Ca-independent PMA No inhibition 0.35 81 14,861 
The same magnitude of IC50 was observed for RAP A in 
Ca-dependent and Ca-independent T-cell proliferation. 
Like RAPA, both MPA and BR inhibit T-cell proliferation 
induced by Ca-dependent and Ca-independent pathways. 
However, compared with RAPA, the IC50 were 102_ and 
lOS-fold higher for MPA and BR, respectively. On the 
other hand. MP A and BR were inhibitory towards Ca-
independent T-cell proliferation at similar IC50 levels as 
observed for Ca-dependent proliferation. The findings sug-
gest that RAP A. MP A. and BR inhibited both T-cell 
activation pathways at similar IC50 values for each drug, 
but the required concentrations ofMPA and BR were 102_ 
and lOs-fold higher than those of RAPA. 
Inhibition of Alloreactive T-Cell Responses by 
Immunosuppressive Drugs 
All four drugs tested (FK 506. CyA. MPA, and BR) 
inhibited the primary MLR responses and the secondary 
PLT proliferation of alloreactive T cells (Table 2). The 
IC50 for FK 506 was 0.1 nmol/L whereas IC50 values for 
MPA and BR were 102_ and lOs-fold higher than for FK 
506. 
Combinations of low Doses of MPA and SR With FK 506 
An additive effect on inhibition of PLT response was 
demonstrated with the combination of MPA (25 ng/mL) 
and FK 506 (0.001 to 0.1 ng/mL) (Fig 1). Similar results 
were achieved with combinations of BR (2,500 ng/mL) and 
FK 506 (0.001 to 0.1 ng/mL) (Fig 1). In contrast. increased 
levels of MP A and BR produced no significant additive 
effects with low doses of FK 506 (data not shown). No 
evidence was obtained for synergism or antagonism be-
tween these drugs in the suppression of PLT proliferation. 
Table 2. Inhibition of Alloreactlve T-Cell Responses by 
Immunosuppressive Drugs 
A1loatimulation 
Primary (MLR) 
Secondary (PL T) 
FK506 
0.1 
0.17 
ICSO (nmoVL) 
CyA 
10 
29 
MPA 
103 
163 
BR 
14,706 
28,751 
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Fig 1. Inhibition of PL T response. Combination of low doses of 
FK 506 (0.01 to 0.1 ng/ml) with (a) MPA (25 ng/ml) and (b) BR 
(2,500 ng/mL). The results are expressed as % inhibition of PL T 
response in the presence of FK 506 alone (0) or in combination 
with MPA or BR (.). 
Effects of Immunosuppressive Drugs on the Proliferation of 
Various Transformed Cell Lines 
Table 3 summarizes the antiproliferative effects of MPA, 
BR. and RAPA on various T-cell lymphomas, EB virus-
transformed B-Iymphoblastoid cell lines. and other tumor 
cell lines. MP A significantly inhibited all cell lines tested at 
drug concentrations of 90 to 365 nmollL. Similar inhibition 
was observed with BR, however, the IC50 dose of BR was 
100 to 200-fold higher than those of MPA. In contrast. 
RAPA exhibited a more restricted spectrum of activity 
than MP and BR. The sensitivity of tumor cell lines to 
RAPA varied from sensitive (EB virus-transformed B-cell 
lines) to more resistant (K562, PEER) (Table 3). 
DISCUSSION 
These data show that MPA and BR inhibit in a dose-
dependent manner the proliferative responses of normal T 
cells to mitogenic and alloantigenic stimulation. Both Ca-
dependent and Ca-independent T-cell activation pathways 
are equally sensitive to MPA and BR immunosuppression. 
In contrast, FK 506 and Cy A are most efficient in blocking 
Ca-dependent T-cell responses.3--5 The drug inhibitory 
activity seems to be cell cycle dependent. Thus, FK 506 
and Cy A act at an early stage of T-cell differentiation by 
inhibiting the cell division cycle at the GJG t interface6 
Table 3. Inhibitory Effects of Immunosuppressive Drugs on the 
Proliferation of Various Transformed Cell Lines 
ICSO (nmollL) 
Cell Culture Origin MPA BR RAPA 
DND41 TLymphoma 91 11,583 NT 
MOLT 13 TLymphoma 365 96,525 274 
PEER T Lymphoma 275 28,275 No inhibition 
EB-DT B Lymphoblast 167 15,984 11 
EB-CK B Lymphoblast 164 25,135 NT 
EB·RK B Lymphoblast 274 46,332 NT 
EB·DN B Lymphoblast 292 42,471 NT 
RPMI-1788 B Lymphoma 182 19,305 10 
K562 Erythroleukemia 304 17,760 No inhibition 
HL-60 Promyelocytic 365 32,007 273 
Note: FK 506 and CyA have no InhibitOlY ellee!. 
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while MPA and BR act at a later stage of cell activation 
pathway by blocking the movement of cells from G 1 to 
S.7.8 Similarly. RAPA acts at a later stage in cell cycle at 
some point in G 1.6 
MP A and BR also block the proliferation of many 
lymphoid and nonlymphoid cell lines. The inhibitory ef-
fects of these drugs are mediated through inhibition of 
ionosin monophosphate phosphatase dehydrogenase. an 
enzyme required for guanine nucleotide synthesis.7.8 
Other drugs known as inhibitors of purine synthesis are 
methotrexate9 and azathioprine. 10 However. the cytostatic 
effects of these drugs are similar for all cell types tested 
(lymphoid cells. fibroblasts. and endothelial cells) whereas 
MPA and BR seem to affect primarily T and B cells.7.8 
Since RAPA significantly inhibited the in vitro expansion 
of EB virus-transformed lymphoblastoid cell lines it is 
likely that RAPA may have clinical efficacy in treating 
EBV -associated posttransplant lymphoproliferative dis-
ease. 
No synergism between MPA or BR with FK 506 or Cy A 
was observed in the inhibition of allogeneic T-cell prolif-
eration. At most. an additive effect was seen with low 
doses of drugs tested in the MLR and PL T test. The 
additive effects have also been reported for combinations 
of Cy A and BR in an in vitro model of CD3-activated T-cell 
proliferationS and in experimental and clinical cadaveric 
renal allotransplantations."·12 Recently. Todo and col-
leagues showed a significant prolongation of renal al-
ZEEVI. WOAN. YAO ET AL 
lografts in dogs treated with low doses of FK S06 and BR 
(personal communication). Thus. MPA and BR may offer 
an alternative regimen when used in conjunction with 
other immunosuppressive drugs in the treatment of al-
lograft rejection. 
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